Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of GSK3196165 in inflammatory hand osteoarthritis
NL-OMON46207Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hand osteoarthritis and erosive hand osteoarthritis (EHOA) comparing GSK3196165 with Placebo (2 arms). Primary endpoint: Change from baseline in 24-hour average hand pain intensity at Week 6. Started May 2016; status: active, not recruiting.
02
Drugs
otilimab
03
Conditions
hand osteoarthritiserosive hand osteoarthritis (EHOA)
Beyond the preview
Go deeper on NL-OMON46207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46207.